{"id":"W4400272774","doi":"10.1200/jco.2024.42.16_suppl.tps4200","title":"REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteria.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Translational Research in Oncology","funders":"","keywords":"Medicine; Regorafenib; Pembrolizumab; Oncology; Internal medicine; Radiology; Nuclear medicine; Colorectal cancer; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003877112,0.002759019,0.003685354,0.0005364615,0.0006003744,0.001348,0.001584315,0.002647928,0.01080171],"category_scores_gemma":[0.00264206,0.0009258342,0.002372134,0.0004925128,0.001871695,0.001670092,0.000908884,0.003946066,0.002220333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000938623,"about_ca_system_score_gemma":0.002333343,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007214772,"about_ca_topic_score_gemma":0.001560628,"domain_scores_codex":[0.998817,0.0007252462,0.00004175919,0.0001486834,0.000101353,0.0001660163],"domain_scores_gemma":[0.997475,0.0005856025,0.0006823436,0.0002298034,0.0001619565,0.0008654017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9754087,0.01112259,0.0005671217,0.0004696943,0.0006282316,0.00004265432,0.00003587335,0.0003614376,0.002295221,0.0001886621,0.001646394,0.007233391],"study_design_scores_gemma":[0.9289446,0.06870081,0.0007132714,0.00001957398,0.0002136514,0.00004007139,0.00001513461,0.0002749898,0.000234128,0.0001188471,0.0007149291,0.00001001776],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9712579,0.00334042,0.001449461,0.001713666,0.0009569447,0.01187069,0.004488355,0.0003510213,0.004571601],"genre_scores_gemma":[0.9426572,0.002917398,0.00584539,0.004702292,0.001633955,0.02642977,0.007932621,0.00009639086,0.007785114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01080171,"threshold_uncertainty_score":0.03613532,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2262371431877061,"score_gpt":0.4505028818403891,"score_spread":0.224265738652683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}